Symrise Announces Terpenes Divestment & Non-Cash Impairment on Swedencare Investment

• Symrise AG plans to divest its terpenes business through a structured bidding process.
• A non-cash impairment charge of approximately EUR 145 million will be recorded in Q4 2025 due to the sale process.
• The investment in Swedencare AB will also be subject to a non-cash impairment of EUR 150 million, impacting the company's expected results for 2025.
• Neither the divestment nor the impairment measures will affect Symrise AG's liquidity or operating business.
• The impairments will be reflected in the earnings reporting and have a negative impact on EBIT and EBITDA.
• The company is in advanced negotiations with potential buyers for its terpenes business, following a structured bidding process.

The next important date, Company Report 2025, at Symrise is on 04.03.2026.

The price of Symrise at the time of the news was 70,36EUR and was up +0,26 % compared with the previous day.
11 minutes after the article was published, the price was 70,12EUR this corresponds to a minus of -0,34 % since publication.
At this time, the index DAX was at 25.413,00PKT (+0,60 %).

Symrise

-0,13 %

-3,09 %

+2,02 %

+6,06 %

-24,83 %

-22,65 %

-27,52 %

+29,95 %

+343,09 %

ISIN:DE000SYM9999WKN:SYM999

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max